-

Genetix Biotherapeutics to Present at Jefferies Global Healthcare Conference

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today announced that the Company will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, at 2:30 p.m. GMT.

David Meek, Chief Executive Officer of Genetix, will provide the first public update on the Company's rapid transformation into a scalable, profitable commercial enterprise, highlighting continued commercial momentum, growth trajectory, and strategic priorities.

About Genetix Biotherapeutics Inc.
Genetix Biotherapeutics Inc. is a privately held, commercial-stage biotechnology company pioneering the field of genetic medicine. With more than 30 years of experience, Genetix is dedicated to delivering transformative, one-time treatments for patients with rare disease, with a focus on hematology. The company has three FDA-approved gene addition cell therapies for sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy, designed to treat the underlying cause of disease with a single dose and deliver durable clinical benefit. Genetix is headquartered in Somerville, Massachusetts.

Website: www.genetixbiotx.com

Contacts

For media inquiries:
Adrian Chaisson
adrian.chaisson@GenetixBioTx.com

Industry:

Genetix Biotherapeutics Inc.

Release Versions
English

Contacts

For media inquiries:
Adrian Chaisson
adrian.chaisson@GenetixBioTx.com

More News From Genetix Biotherapeutics Inc.

Genetix Biotherapeutics Appoints Meredith Manning as Chief Commercial Officer

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today announced the appointment of Meredith Manning as Chief Commercial Officer. Ms. Manning will lead commercial strategy and execution for the company’s portfolio of FDA-approved one-time gene addition cell therapies. “Meredith is an exceptional commercial leader with a proven track record of driving growth while delivering meaningful impact...

Genetix Biotherapeutics and the National Football League Alumni Association Announce Partnership to Increase Awareness for Sickle Cell Disease and Transformative Treatment Options

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. and the National Football League Alumni Association today announced a partnership to launch a national awareness and education initiative for sickle cell disease. Through community engagement, the partnership will raise greater awareness of the difficulties of living with sickle cell disease, while helping individuals, families, and healthcare providers better understand available treatment options and support services. Many famil...

Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. and the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) and its wholly owned subsidiary, SPIMACO Bio, today announced an exclusive collaboration and license agreement for the development, commercialization, and localized manufacturing of LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and across the broader Middle East. LYFGENIA and ZYNTEGLO are first-in-class, one-time gene addition cell therapies for the tre...
Back to Newsroom